First FDA-approved MacTel treatment performed

Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the first and only FDA-approved treatment for adults with idiopathic macular telangiectasia type 2 (MacTel), ENCELTO (revakinagene taroretcel-lwey).¹